Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-3.50% $12.39
America/New_York / 8 mai 2024 @ 14:41
FUNDAMENTALS | |
---|---|
MarketCap: | 946.38 mill |
EPS: | -1.210 |
P/E: | -10.24 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 76.38 mill |
Avg Daily Volume: | 0.827 mill |
RATING 2024-05-08 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -10.24 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.74x |
Company: PE -10.24 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-11.11 (-189.70%) $-23.50 |
Date: 2024-05-08 |
Expected Trading Range (DAY) |
---|
$ 11.62 - 13.16 ( +/- 6.18%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-19 | Saggar Rajeev | Sell | 1 649 | Common Stock |
2024-04-12 | Schundler Russell | Sell | 2 060 | Common Stock |
2024-04-12 | Saggar Rajeev | Sell | 1 525 | Common Stock |
2024-04-12 | Moomaw Scott | Sell | 1 585 | Common Stock |
2024-04-12 | Kaseta Michael | Sell | 3 136 | Common Stock |
INSIDER POWER |
---|
76.54 |
Last 99 transactions |
Buy: 2 738 617 | Sell: 339 337 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $12.39 (-3.50% ) |
Volume | 0.273 mill |
Avg. Vol. | 0.827 mill |
% of Avg. Vol | 33.05 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $14.57 | N/A | Active |
---|
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.